Latest Conference Articles

February 13th 2021, 6:41pm

Genitourinary Cancers Symposium (ASCO GU)

Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.

February 13th 2021, 4:44pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.

February 13th 2021, 3:36pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.

February 13th 2021, 3:09pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.

February 13th 2021, 1:06am

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

February 13th 2021, 12:33am

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Cabozantinib demonstrated significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma who have brain metastases.

February 13th 2021, 12:22am

Genitourinary Cancers Symposium (ASCO GU)

Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.

February 13th 2021, 12:01am

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

February 12th 2021, 11:44pm

Genitourinary Cancers Symposium (ASCO GU)

Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

February 12th 2021, 9:30pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Tivozanib led to a significantly greater quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy versus sorafenib in patients with metastatic renal cell carcinoma.

February 12th 2021, 8:23pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.

February 12th 2021, 7:45pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Atezolizumab monotherapy showed favorable outcomes compared with chemotherapy alone as frontline treatment for patients with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma.

February 12th 2021, 7:38pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.

February 12th 2021, 6:25pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

February 12th 2021, 5:24pm

Genitourinary Cancers Symposium (ASCO GU)

February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib

February 12th 2021, 4:38pm

Transplantation and Cellular Therapy Meetings

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

February 11th 2021, 11:08pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.

February 11th 2021, 11:05pm

Genitourinary Cancers Symposium (ASCO GU)

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

February 11th 2021, 11:03pm

Genitourinary Cancers Symposium (ASCO GU)

February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

February 11th 2021, 10:59pm

Transplantation and Cellular Therapy Meetings

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.